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The liver is an organ at risk (OAR) in radiotherapy of thoracic and abdominal tumors such as gastric, 
distal esophagus, lower lung and breast, bile duct, pancreas and whole abdomen. In this study the 
alteration in liver functional tests (LFT) of these patients during radiotherapy was investigated. To that 
end, the level of serum aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline 
phosphatase (ALP), direct and total bilirubin were checked out at different times (before radiotherapy and 
every 2 weeks after the start of radiotherapy and followed up to 2 months after the end of treatment). The 
results showed that LFT level increased during radiotherapy while they gradually decreased after 
treatment. Our results showed that the LFT serum is a very sensitive and useful biomarker for evaluation 
of the radiotherapy effects. 
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INTRODUCTION 
     Radiation therapy is an integral part of the 
treatment of patients inflicted with cancer. It is 
estimated that over 60% of patients with cancer 
will have radiotherapy as part of their total 
course of treatment. Radiation therapy affects 
both tumor cells and uninvolved normal cells 
[1]; the former benefits through killing tumor 
cells but the later leads to detriment of patient as 
it causes some significant complications in 
patients. Although the liver was once believed to 
be relatively Radioresistant, hepatic 
morphologic and functional alterations have 
been observed after radiation therapy 
[2,3].Hepatic radiation is most often 
unintentional and occurs when the liver is 
unavoidably included in the treatment portal for 
lower breast and lung, distal esophageal, gastric, 
bile duct, pancreatic carcinoma or lymphoma 
and whole body. Patients who receive a single 
12Gy dose of external beam radiation or 40 to 
55Gy fractionated dose over 6 weeks can 
develop radiation Hepatitis. Nearly 75% of 
patients receiving whole liver irradiation have 
abnormal liver function tests [3,4].After 
radiotherapy for cancers of the abdominal and 
lower thoracic, the interpretation of changes in 
the liver functional tests (LFT) during follow up 
can be problematic [5]. Some observer have 
associated alteration in LFT with visible 
vascular or density temporary modification in 
irradiated liver regions [6], suggesting a possible 
alternative origin for LFT abnormalities in 
patients with no sign of metastasis [5].If the area 
of irradiated hepatic tissue is small, the classic 
signs and symptoms of hepatic radiation injury 
such as hepatomegaly and ascites are not 
present. If the liver receives high doses of 
radiation during childhood, atrophy may result. 
If other structures such as the kidney or vertebral 
bodies are included in the part, they are 
underdeveloped as well [3].Radiation–induced 
liver disease (RILD) has been reported to be one 
of the most important complications in patients 
who undergo abdominal and lower thoracic 
radiotherapy and limiting dose escalation is a 
major factor for liver irradiation [7].The purpose 
of this study was to analyze LFT and hepatic 
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dysfunction after radiotherapy in patients with 
abdominal and lower thoracic cancers and to 
determine the relationship between hepatic 
dysfunction and liver dose.  
 
PATIENTS AND METHOD  
     The present study was carried out on 123 
patients who received radiotherapy for 
abdominal and lower thoracic cancers (e.g. 
gastric, distal esophagus, pancreas, bile duct, 
right breast and lung,…) from December 2014 
to October 2015 in Tohid hospital,  Sanandaj. 
There were 64 women and 59 men with the age 
range between 27 to 90 years (mean 57 years). 
The patients had not history of liver metastasis 
or other liver disease. Of the 123 patients, 40 
cases (%32.5) had esophagus tumor, 30 cases 
(%24.4) had breast cancer, 27 cases (%22) had 
gastric tumor and 26 cases (%21.1) had other 
tumors. 83 patients received chemotherapy 
before radiotherapy and others received chemo 
radiotherapy. Concomitant chemotherapy was 
administered to all patients either as continuous 
5FU infusion (250-300 mg/m²/d for adjuvant 
gastric adenocarcinomas, extra hepatic 
cholangiocarcinoma and adjuvant pancreatic 
carcinoma) or as a combination of weekly 
administrations of Cisplatin or Carboplatin with 
a continuous 5FU infusion (250 mg/m²/d) for 
locally advanced pancreatic adenocarcinomas. 
Irradiation was done by 3D conformal 
radiotherapy based on a simulation CT and 
calculated with the same TPS (Isogray version 
4.1 from Dosisoft Company). Treatment carried 
out with an Elekta machine producing x-ray 
beams of 6 to 15 MV. Most of these patients 
delivered 45 to 50.4 Gy. The fraction size 
ranged from 1.8 to 2 Gy (median 2 Gy) for 5 
days per week. The planning target volume was 
defined as the CTV (Clinical Target Volume) 
plus an approximate 1-2cm margin in all 
directions. To evaluate the effect of radiotherapy 
on Liver Functional Tests (LFT) including ALT, 
AST, and ALP, direct and total bilirubin levels 
before and after radiotherapy were analyzed. 
These tests were included on most routine 
laboratory tests. The combined elevation of 
these enzymes indicates the presence of liver 
disease Blood tests were examined 0-14 days 
before the start of radiotherapy (median 1 day). 
Patients had blood tests every 2 weeks (weeks 2, 
4, and 6) after start of radiotherapy. In addition 
these patients followed up for 2 months after 
radiotherapy. Statistical tests were performed 
using the SPSS software (version 23). A P-value 
of <0.05 was considered to indicate statistical 
significance. Cases where transaminase or ALP 
levels exceeded the normal upper limits slightly 
after radiation were not of clinical significance. 
Cases where transaminase or ALP levels elevate 
more than double pretreatment values and 
exceed normal limits after radiation were also 
not of clinical significance if the 
pretreatment values were low. All the steps 
of this study, including sampling, data 
collection, and broadcasting the study results 
in the form of article are done with the full 
consent of the patients. 
 RESULT 
     In this study, 123 patients have been treated 
by three-dimensional conformal radiotherapy for 
abdominal and lower thoracic cancers. Patients 
age ranged from 27 to 90 years (mean 57 years). 
15 patients received 1.8 Gy per fraction and 
others received 2 Gy. Maximal doses received to 
PTVs ranged from 45 to 50.4 Gy. None of the 
patients had hepatic disorders such as chronic 
hepatitis or hepatic tumors. The average level of 
serum ALT , AST , ALP , direct and total 
bilirubin with the statistical significance of 
standard deviation are given in table 1.Mean 
pre-radiotherapy LFTs were in the normal 
range. LFT activity was raised after start of 
radiotherapy [Figs 1-5]. There was a 
statistically significant increase (P<0.05) in 
serum level of LFTs. Maximal level of LFTs 
was observed at the end of treatment (mean 
32th day after start of treatment). These liver 
tests values between pretreatment and post 
treatment were significantly different.  LFT 
levels decreased afterwards and most tests of 
patients got nearly normalized. The figures 
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Table 1. Alteration in liver functional tests of patients with abdominal and thoracic tumors during radiotherapy. All values are the mean. 
±SD  
 
   
 
Figure 1. Alteration serum ALT level after radiotherapy                                          
                          
 
Figure 3. Alteration serum ALP level after radiotherapy 
 
 
        Figure 2.Alteration serum AST level after radiotherapy                                     
            
                       
Figure 4. Alteration serum bilirubin (D) level after 
radiotherapy                                  
 
LFT             normal range            pre radiotherapy        14 days           28 days           42 days         72 days         102 
days    
ALT                   5-40 (u/l)                      26.29±3.93               27.25±3.94         33.23±4.44         41.02±5.7           37.55±5.38           
33.64±4.9 
AST                   7-65 (u/l)                      25.88±3.21               26.22±2.96         31.33±3.89         36.85±4.97         35.07±4.57          
31.93±4.14 
ALP                   50-150 (u/l)                  228.63±20.06           240.5±18.79       247.72±18.42     265.57±19.87    252.87±18.09      
236.45±17.53 
Bilirubin(D)     0.1 – 0.3 (mg/dl)          0.18±0.03                  0.19±0.02            0.22±0.02           0.24±0.03           0.21±0.03            
0.20±0.03 
Bilirubin(T)      0.3 - 1 (mg/dl)             0.6±0.04                    0.62±0.05            0.65±0.05           0.68±0.05           0.65±0.05            
0.62±0.04     
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Figure  5.Ateration serum bilirubin (T) level after 
radiotherap 
Pretreatment ALT values for 11 patients and AST 
values for 6 patients were more than normal 
levels. Transaminase levels increased gradually 
during radiation therapy. A more than 1.5 five-
fold increase for ALT and 1.42 five-fold increase 
for AST levels were observed at the end of 
radiotherapy. Then transaminase levels decreased 
at post radiotherapy. 101 patients (%82) had 
abnormal ALP levels prior to treatment. After 
start of radiation therapy, ALP level increased and 
it received to 1.16 five-fold normal level at the 
end days of treatment. Pretreatment total bilirubin 
values in 9 patients were above normal range. 
Direct and total bilirubin raised post treatment and 




     Liver is one of the main organs at risk for 
many abdominal and lower thoracic tumors 
undergoing radiotherapy [7,8]. When these 
tumors received radiation, a part of the liver is 
placed in the field treatment. Liver receives high 
dose radiation if it is placed in the vicinity of the 
tumor. Therefore reduction in treatment volume 
of these serial organs is critically important [9]. 
The present study evaluated changes in the LFT 
level in these patients. First LFT level was 
checked before radiotherapy then these patients 
were followed up every 2 weeks towards the end 
of treatment. In addition these patients were 
followed up for 1 month and 2 months after the 
end of radiotherapy.Reference values for human 
were displayed as 5 – 40 (u/l) for ALT, 7 – 65  
(u/l) for AST, 50 – 150 (u/l) for ALP, 0.1 – 0.3 
(mg/dl) for direct bilirubin and 0.3 – 1 (mg/dl) for 
total bilirubin.The results of this study confirmed 
that liver radiation induced LFT changes. Rate of 
changes was different in patients [10]. In the 
previous studies, some  recorded an elevated 
activity while others showed a decrease activity. 
Jin hong jung et al , Matthew H.stenmark et al , 
Hidekaju nakata et al and Jaggandha Rao Peela et 
al reported that liver radiation increased LFT level 
[7, 11-13] but Tadej Dovsak et al , Saung – Gu 
Yeo et al , Kultigin Cavusoglu showed that liver 
radiotherapy caused a decrease in LFT level 
[14,16].The present study showed that radiation 
elevated serum LFT levels. LFT levels increased 
gradually during radiotherapy and it reached its 
peak at the end of treatment. Regression 
coefficient showed relationship between 
dependent variables (liver tests) and all studied 
independent variable. It discovered that factors 
such as patient's age, liver dose, chemotherapy 
and treatment duration had the most effect on the 
LFT levels. The liver function tests are very 
important for diagnosis, evaluation of severity and 
correct management of radiation – induced injury 
even with the fluctuations observed. It is difficult 
to explain the changing mechanism of serum LFT 
parameters. It is likely that these increases could 
be related to cell destruction [16]. As is known 
LFT are synthesized by hepatocyte cells and are 
sensitive and specific enzymes for liver disease 
[19]. Any elevation in these levels may be 
commented as an indicator of liver disease [16-
18]. Therefore the simultaneous increase in LFT 
levels during radiotherapy may probably be 
related to radiation – induced liver injury. 
  
CONCLUSION 
     This study indicated that radiotherapy for 
abdominal and thoracic tumors increased LFT 
levels; it can also be concluded that radiation 
damages healthy cells, leading to liver 
dysfunction. Radiotherapy treatment should 
be planned in order to reduce liver dose. Dose 
restriction for healthy liver should be further 
evaluated. 
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